Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
28.67
+0.14 (0.49%)
Jul 21, 2026, 1:31 PM EDT - Market open
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
According to 19 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $52.53. The average 1-year stock price forecast is 83.22% higher than the current stock price, while the lowest is $25 (-12.80%) and the highest is $96 (+234.84%).
Price Target: $52.53 (+83.22%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 13 | 13 | 12 | 12 | 12 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 20 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Reiterates $48 | Buy | Reiterates | $48 | +67.42% | Jul 15, 2026 |
| Wedbush | Wedbush | Hold Reiterates $26 → $30 | Hold | Reiterates | $26 → $30 | +4.64% | Jul 13, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +39.52% | Jul 7, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $72 | Buy | Maintains | $72 | +151.13% | Jul 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $79 | Buy | Maintains | $79 | +175.55% | Jun 10, 2026 |
Financial Forecast
Revenue This Year
741.48M
from 673.00M
Increased by 10.18%
Revenue Next Year
984.99M
from 741.48M
Increased by 32.84%
EPS This Year
-4.24
from -5.83
EPS Next Year
1.55
from -4.24
EPS and Forward PE are based on non-GAAP adjusted numbers.